Bionano Genomics Inc (BNGO) — Cash Flow-to-Debt Ratio
Latest as of June 2026:
-0.29x
Bionano Genomics Inc (BNGO) has a Cash Flow-to-Debt Ratio of -0.29x as of June 2026, meaning its operating cash flow of $-4.67 Million could theoretically repay 0% of its total liabilities ($15.98 Million) in one year. See Bionano Genomics Inc free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.29x
Operating CF / Total Liabilities
Operating Cash Flow
$-4.67 Million
USD
Total Liabilities
$15.98 Million
USD
Data as of
Jun 2026
Most recent filing
Bionano Genomics Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Bionano Genomics Inc across 10 annual periods. For the full cash flow conversion analysis, see Bionano Genomics Inc cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for Bionano Genomics Inc (2016–2025)
Year-by-year debt coverage analysis for Bionano Genomics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.56x | $-16.34 Million | $29.16 Million | ▲ +66.4% |
| 2024 | -1.67x | $-68.92 Million | $41.30 Million | ▼ -57.7% |
| 2023 | -1.06x | $-125.18 Million | $118.25 Million | ▲ +50.7% |
| 2022 | -2.15x | $-124.82 Million | $58.10 Million | ▼ -19.4% |
| 2021 | -1.80x | $-71.93 Million | $39.98 Million | ▼ -19.1% |
| 2020 | -1.51x | $-38.31 Million | $25.37 Million | ▼ -36.0% |
| 2019 | -1.11x | $-29.53 Million | $26.59 Million | ▲ +18.4% |
| 2018 | -1.36x | $-19.94 Million | $14.67 Million | ▼ -294.4% |
| 2017 | -0.34x | $-20.82 Million | $60.37 Million | ▲ +38.3% |
| 2016 | -0.56x | $-23.50 Million | $42.05 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.